Literature DB >> 9527887

Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors.

R L Klein1, E M Meyer, A L Peel, S Zolotukhin, C Meyers, N Muzyczka, M A King.   

Abstract

Viral vector-mediated gene transfer in brain can provide a means for gene therapy and functional studies. However, robust and persistent transgene expression in specific populations of the adult brain has been difficult to achieve. In an attempt to produce localized and persistent transduction in rat brain, we compared recombinant adeno-associated virus (rAAV) vectors incorporating either the immediate early cytomegalovirus (CMV) promoter or the neuron-specific enolase (NSE) promoter. Transduction in hippocampus resulting from the NSE promoter-containing construct was more efficient and persistent than that resulting from the CMV promoter-containing construct. Most hippocampal cells transduced with the NSE promoter had multipolar neuron morphology. Neurons with glutamatergic morphology were transduced weakly. In order to produce a local supply of neurotrophic factor to cells that degenerate under certain disease and experimental conditions, the NSE promoter was utilized to drive expression of brain-derived neurotrophic factor (BDNF) in medial septum or substantia nigra. In this construct, the NSE promoter drives dicistronic expression of BDNF and an enhanced version of green fluorescent protein (GFP). We estimated 3000-15,000 GFP-positive cells per injection of rAAV into septum or substantia nigra, a transduction ratio of 5-20 infectious virus particles per transduced cell. This frequency may be sufficient for trophic factor gene therapy as well as for investigating specific protein function in "topical (i.e., localized) transgenic" animals produced by rAAV. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527887     DOI: 10.1006/exnr.1997.6736

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  56 in total

1.  Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.

Authors:  M Moskalenko; L Chen; M van Roey; B A Donahue; R O Snyder; J G McArthur; S D Patel
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector.

Authors:  M A Passini; J H Wolfe
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Adenosine kinase as a target for therapeutic antisense strategies in epilepsy.

Authors:  Panos Theofilas; Sukhmani Brar; Kerry-Ann Stewart; Hai-Ying Shen; Ursula S Sandau; David Poulsen; Detlev Boison
Journal:  Epilepsia       Date:  2011-01-28       Impact factor: 5.864

4.  A herpes simplex viral vector expressing green fluorescent protein can be used to visualize morphological changes in high-density neuronal culture.

Authors:  Torsten Falk; Lori A Strazdas; Rebecca S Borders; Ramsey K Kilani; Andrea J Yool; Scott J Sherman
Journal:  Electron J Biotechnol       Date:  2001-04-15       Impact factor: 2.800

5.  Projections of preBötzinger complex neurons in adult rats.

Authors:  Wenbin Tan; Silvia Pagliardini; Paul Yang; Wiktor A Janczewski; Jack L Feldman
Journal:  J Comp Neurol       Date:  2010-05-15       Impact factor: 3.215

6.  Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons.

Authors:  Matthew R J Mason; Erich M E Ehlert; Ruben Eggers; Chris W Pool; Stephan Hermening; Angelina Huseinovic; Eric Timmermans; Bas Blits; Joost Verhaagen
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 7.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

8.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.

Authors:  Ronald L Klein; Robert D Dayton; Nancy J Leidenheimer; Karen Jansen; Todd E Golde; Richard M Zweig
Journal:  Mol Ther       Date:  2005-12-01       Impact factor: 11.454

Review 9.  Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

Authors:  Ronald J Mandel; Corinna Burger; Richard O Snyder
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

Review 10.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.